---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-152039"
form_type: "8-K"
ticker: "RVMD"
cik: "0001628171"
company_name: "Revolution Medicines, Inc."
filed_at: "2026-04-13T23:59:59+00:00"
generated_at: "2026-05-15T06:35:27.463900+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Revolution Medicines' daraxonrasib Phase 3 trial meets OS endpoint: 13.2 vs 6.7 months, HR 0.40

## Summary
- Phase 3 RASolute 302 trial: median OS 13.2 mo vs 6.7 mo for chemo (HR 0.40, p<0.0001); PFS also statistically significant.
- Daraxonrasib generally well tolerated with manageable safety profile; no new safety signals.
- Trial results considered final from first interim analysis; company to submit to FDA and other global regulators.
- Data to support future NDA via a Commissioner’s National Priority Voucher.

## SEC filing metadata
- accession: 0001193125-26-152039
- form_type: 8-K
- ticker: RVMD
- cik: 0001628171
- company_name: Revolution Medicines, Inc.
- filed_at: 2026-04-13T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1628171/000119312526152039/0001193125-26-152039-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1628171/000119312526152039/d69348d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-152039
- JSON: https://secwatch.observer/filing/0001193125-26-152039.json
- Plain text: https://secwatch.observer/filing/0001193125-26-152039.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.